Third phase III Sativex® cancer pain trial commences GW’s cancer pain clinical programme is being wholly funded by Otsuka Pharmaceutical Co. Ltd, which has licensed the US commercialisation rights to this product. The trials are designed to obtain approval in this indication from the Food & Drug
Barcelona, Spain; Porton Down, UK; 8th May 2012: GW Pharmaceuticals plc (AIM:GWP) and Almirall S.A. (ALM) today announce the successful completion of the European Mutual Recognition Procedure (MRP) for Sativex® oromucosal spray in the treatment of spasticity due to Multiple Sclerosis (MS).
London, UK; Tokyo, Japan; April 23 2012: GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce the publication in the Journal of Pain(1), the official journal of the American Pain Society, of the full results from a Phase IIb dose-ranging trial evaluating the efficacy
Porton Down, UK; 16 April 2012: GW Pharmaceuticals plc (AIM: GWP) confirms that it has now earned the €11.9 million milestone payment due as a result of the recently amended terms of its licence agreement with Almirall S.A. (announced on 15 March 2012).
Professor Vincenzo Di Marzo to direct GW’s global pre-clinical research programme Porton Down, UK; 8 March 2012: GW Pharmaceuticals plc (AIM: GWP) today announces that, effective March 1st 2012, Professor Vincenzo Di Marzo has agreed to direct GW’s global pre-clinical research programme and will
Sativex regulatory approval received in Austria Porton Down, UK; 7 February 2012: GW Pharmaceuticals plc (AIM: GWP) today announces a regulatory update for Sativex® (Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) oromucosal spray. Sativex ® has received regulatory approval in Austria as a